New Strategy for anti-HBV therapy: blocking P-8 interaction.
- Author:
Ya-yun HUANG
;
Kang-hong HU
- Publication Type:Journal Article
- MeSH:
Animals;
Gene Expression Regulation, Viral;
Gene Products, pol;
antagonists & inhibitors;
genetics;
metabolism;
Hepatitis B;
therapy;
virology;
Hepatitis B virus;
enzymology;
genetics;
physiology;
Humans;
RNA, Viral;
genetics;
metabolism;
Virus Replication
- From:
Chinese Journal of Virology
2014;30(6):713-720
- CountryChina
- Language:Chinese
-
Abstract:
Clinically being applied treatment against chronic hepatitis has three limitations: low response rates, severe adverse effects and a high rate of drug resistance. Hence, novel targets for antiviral therapy need to be developed so as to provide an armory of different strategies. During the replication of hepatitis B virus, the interaction of viral polymerase (P protein, also called P) and epsilonRNA is indispensable for the initiation of reverse transcription via protein priming and the pregenome RNA (pgRNA) packaging. Three strategies are currently developed for blocking P-epsilon interaction: heat shock protein inhibitors, epsilonaptamers and chemical compounds for blocking formation of P-epsilon complex. Previously, our group has for the first time worldwide in vitro screened several aptamers, which are able to interfere with the P-epsilon interaction. A strong inhibition against HBV was observed in vitro and in vivo experiments, respectively. In conclusion, the so far developed chemicals suppressing the P-epsilon interaction may bypass or overcome the viral resistance problems during clinic treatment and represent a highly attractive option for therapeutic intervention.
